Volume 14, Number 6—June 2008
Ceftriaxone-Resistant Salmonella enterica Serotype Newport, France
Highlight and copy the desired format.
|EID||Egorova S, Timinouni M, Demartin M, Granier SA, Whichard JM, Sangal V, et al. Ceftriaxone-Resistant Salmonella enterica Serotype Newport, France. Emerg Infect Dis. 2008;14(6):954-957. https://dx.doi.org/10.3201/eid1406.071168|
|AMA||Egorova S, Timinouni M, Demartin M, et al. Ceftriaxone-Resistant Salmonella enterica Serotype Newport, France. Emerging Infectious Diseases. 2008;14(6):954-957. doi:10.3201/eid1406.071168.|
|APA||Egorova, S., Timinouni, M., Demartin, M., Granier, S. A., Whichard, J. M., Sangal, V....Weill, F. (2008). Ceftriaxone-Resistant Salmonella enterica Serotype Newport, France. Emerging Infectious Diseases, 14(6), 954-957. https://dx.doi.org/10.3201/eid1406.071168.|
The multidrug-resistant (MDR) Salmonella enterica serotype Newport strain that produces CMY-2 β-lactamase (Newport MDR-AmpC) was the source of sporadic cases and outbreaks in humans in France during 2000–2005. Because this strain was not detected in food animals, it was most likely introduced into France through imported food products.
Third-generation cephalosporins are drugs of choice for treatment of persons with nontyphoidal Salmonella infections that require chemotherapy or when fluoroquinolones are contraindicated. A new public health concern is the emergence of third-generation cephalosporin–resistant Salmonella isolates (1). Multidrug-resistant (MDR) Salmonella enterica serotype Newport isolates that produce CMY-2, a β-lactamase that inactivates third-generation cephalosporins, were first reported in the United States in 1998 (2). These isolates, known as Newport MDR-AmpC, have quickly spread through the United States in cattle and humans (3–5). It has been hypothesized that use of ceftiofur, a third-generation cephalosporin licensed in the United States for use in cattle, could have selected for Newport MDR-AmpC (2–4,7). Several observations and case-control studies suggested beef and milk from dairy cattle were substantial sources of Newport MDR-AmpC infection in humans (6–8).
These isolates seem to be extremely rare in Europe. Two surveys performed in England and Wales (278,308 human Salmonella isolates tested, 1992–2003) and Spain (959 human Salmonella isolates, 1999–2000) did not detect Newport MDR-AmpC (9,10). In St. Petersburg, Russia, only 1 Newport MDR-AmpC isolate was reported among 1,078 Salmonella isolates during 2002–2005 (11). In France, a small outbreak (14 cases) of Newport MDR-AmpC was detected in 2003 and linked to consumption of imported horse meat (12). We undertook the present study to acquire more knowledge on circulation of Newport MDR-AmpC in humans, animals, and animal-derived food in France.
From 2000 through 2005, the French National Reference Centre for Salmonella at the Institut Pasteur in Paris reported 829 Newport isolates among 69,759 Salmonella clinical isolates. During this period and depending on the year, serotype Newport ranked between 6th and 10th in prevalence among human serotyped isolates. From 2000 through 2005, the Agence Française de Sécurité Sanitaire des Aliments reported 2,160 Newport isolates among 101,791 Salmonella isolates collected from animals and food products.
Antimicrobial drug susceptibility testing was performed on 585 human Newport isolates and 342 nonhuman Newport isolates by disk diffusion with 32 antimicrobial drugs (additional information available from firstname.lastname@example.org). Data for Newport human isolates are shown in the Table. Of 585 isolates tested, 46 (7.9%) were resistant to third-generation cepalosporins. The geographic origin of the isolates was mainly the Paris metropolitan area and northern France (Appendix Table [PDF - 37 KB]). There was a high prevalence of third-generation cephalosporin–resistant isolates during 2000 (15%) and 2003 (17.5% caused by a small outbreak). No third-generation cephalosporin resistance was detected in any of the nonhuman Newport isolates tested.
Experiments were performed on the 46 third-generation cephalosporin–resistant Newport isolates (additional information available from email@example.com). All but 1 of the Newport isolates were resistant to cefoxitin (Appendix Table [PDF - 37 KB]). These isolates showed 4 resistance phenotypes; most (41, 89.1%) were resistant to streptomycin, sulfonamides, chloramphenicol, and tetracycline. PCR and sequencing showed that the 45 isolates resistant to cefoxitin were positive for the blaCMY-2 gene, and cefoxitin-susceptible isolates contained the extended-spectrum β-lactamase gene blaCTX-M-1. Ceftriaxone MICs of Newport MDR-AmpC isolates ranged from 32 mg/L to >256 mg/L, and ceftazidime MICs ranged from 64 mg/L to >256 mg/L. No blaTEM genes were detected. Three isolates with additional resistance to aminoglycosides contained a class 1 integron with the 1-kb gene cassette aadA24 (known to encode resistance to streptomycin and spectinomycin) (11). The chloramphenicol/florfenicol resistance gene floR was detected in all but 1 CMY-2–producing Newport isolate.
Clonal relatedness of Newport isolates was assessed by multilocus sequence typing (MLST) and PulseNet standard method pulsed-field gel electrophoresis (PFGE) (Figure 1). All 16 Newport MDR-AmpC isolates tested had a common sequence type (ST), ST45. XbaI-PFGE identified 10 distinct profiles (similarity 76.7%) among all 45 Newport MDR-AmpC isolates. Single enzyme matches were found for 3 of the profiles (15 isolates) in the US PulseNet national database (www.cdc.gov/pulsenet; Appendix Table [PDF - 37 KB]; Figure 2). Two PFGE types (New6 and New8) were divided into 2–4 subtypes because of additional band(s) <100 kb. Isolates from the 2003 outbreak showed 4 similar but distinct PFGE profiles that differed by 1–2 bands, migrated between 60 and 100 kb, and were attributed to plasmid(s) (additional information available from firstname.lastname@example.org). If only cases with indistinguishable PFGE profiles had been tested, potentially related cases would not have been linked to this outbreak. Therefore, during an outbreak investigation of Newport MDR-AmpC, analysis of plasmid content (either by alkaline lysis or S1 nuclease, depending on size of additional bands) might complete XbaI-PFGE profiles for isolates whose profiles differ by 1 or 2 additional bands of low molecular mass.
Alkaline lysis extraction showed that all but 1 of the Newport MDR-AmpC isolates harbored a plasmid >125 kb that hybridized with a blaCMY-2 probe; the remaining isolate harbored a plasmid of 100 kb (Appendix Table [PDF - 37 KB]). Analysis with S1 nuclease showed that these plasmids were 100 kb–370 kb. Up to 3 additional plasmids (3.5 kb–100 kb) that did not have blaCMY-2 were detected in most isolates (Appendix Table [PDF - 37 KB]). Cephalosporin resistance was transferred by electroporation of plasmid DNA to Eschericha coli DH10B for all 38 CMY-2–positive isolates tested. When present in the donor strain, resistance to sulfonamides, chloramphenicol, and tetracycline was also transferred. Restriction analysis of plasmids isolated from transformants showed 6 similar restriction profiles for Newport isolates (R1–R6) (Figure 2, Appendix Table [PDF - 37 KB]). R1 was predominant (found in 26 isolates among 35 tested, 74.3%). Newport plasmids R1–R6 and Agona plasmid R8 were shown by PCR to contain variant A/C2 replicons (13), whereas Typhimurium plasmid R7 contained the I1 replicon.
PstI-digested plasmids analyzed by Southern hybridization with a blaCMY-2 probe (Figure 2) showed 4 hybridization profiles among Newport isolates. Profile H1 corresponded to plasmid type C described by Carattoli et al. (14). Profiles H2, H3, and H4 differed from H1 by 1 additional band (>10 kb for H2, 3.2 kb for H3, and >18 kb for H4), which indicated that the blaCMY-2 gene was partially or totally duplicated.
Newport MDR-AmpC isolates have been the source of sporadic cases and small outbreaks in humans in France during 2000–2005. All isolates had the same MLST type, ST45, and highly similar XbaI-PFGE profiles. Their plasmids carrying blaCMY-2 were homogeneous (same incompatibility group A/C2, a main restriction type R1, and a main hybridization type H1). These results support clonal expansion of 1 Newport strain (or a limited number of genetically related Newport strains) able to acquire and maintain a large incA/C2 MDR plasmid.
The source of the French isolates remains unknown. However, this strain was not found in French food animals or domestically produced food products (additional information available from email@example.com). One outbreak during the study period was linked to imported horse meat. Further investigation identified the source as a wholesaler who imported meat from Belgium, the United Kingdom, Hungary, Canada, Brazil, Argentina, Uruguay, and Australia (12). In contrast to Europe, Newport MDR-AmpC has been frequently seen in the United States during the past decade. Furthermore, several characteristics were shared between US and French Newport MDR-AmpC isolates: ST45 (15), PFGE profiles New5, New6a, and New6b (displayed by 15 isolates among the 45 studied), and blaCMY-2 plasmid hybridization type H1 (14). We can reasonably hypothesize that during 2000–2005 some isolates likely entered France from North America through imported food. Alternatively, they could have come to France and North America from some other country.
Dr Egorova is a microbiologist in the laboratory of intestinal infections at the Institut Pasteur in St. Petersburg, Russia. Her primary research interests are molecular epidemiology and antimicrobial resistance surveillance of S. enterica.
We thank all corresponding laboratories of the French National Reference Centre for Salmonella and the Agence Française de Sécurité Sanitaire des Aliments networks for participation in the study, and Peter Gerner-Smidt for comparing PFGE profiles with those of the PulseNet USA database.
S.E. and M.T. were supported by a grant from the Réseau International des Instituts Pasteur.
- Arlet G, Barrett TJ, Butaye P, Cloeckaert A, Mulvey MR, White DG. Salmonella resistant to extended-spectrum cephalosporins: prevalence and epidemiology. Microbes Infect. 2006;8:1945–54.
- Dunne EF, Fey PD, Kludt P, Reporter R, Mostashari F, Shillam P, Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with AmpC beta-lactamase. JAMA. 2000;284:3151–6.
- Rankin SC, Aceto H, Cassidy J, Holt J, Young S, Love B, Molecular characterization of cephalosporin-resistant Salmonella enterica serotype Newport isolates from animals in Pennsylvania. J Clin Microbiol. 2002;40:4679–84.
- Zhao S, Qaiyumi S, Friedman S, Singh R, Foley SL, White DG, Characterization of Salmonella enterica serotype Newport isolated from humans and food animals. J Clin Microbiol. 2003;41:5366–71.
- Whichard JM, Joyce K, Fey PD, Nelson JM, Angulo FJ, Barrett TJ. Beta-lactam resistance and Enterobacteriaceae, United States. Emerg Infect Dis. 2005;11:1464–6.
- Fey PD, Safranek TJ, Rupp ME, Dunne EF, Ribot E, Iwen PC, Ceftriaxone-resistant Salmonella infection acquired by a child from cattle. N Engl J Med. 2000;342:1242–9.
- Gupta A, Fontana J, Crowe C, Bolstorff B, Stout A, Van Duyne S, The National Antimicrobial Resistance Monitoring System PulseNet Working Group. Emergence of multidrug-resistant Salmonella enterica serotype Newport infections resistant to expanded-spectrum cephalosporins in the United States. J Infect Dis. 2003;188:1707–16.
- Varma JK, Marcus R, Stenzel SA, Hanna SS, Gettner S, Anderson BJ, Highly resistant Salmonella Newport-MDRAmpC transmitted through the domestic US food supply: a FoodNet case-control study of sporadic Salmonella Newport infections, 2002–2003. J Infect Dis. 2006;194:222–30.
- Batchelor M, Hopkins KL, Threlfall EJ, Clifton-Hadley FA, Stallwood AD, Davies RH, Characterization of AmpC-mediated resistance in clinical Salmonella isolates recovered from humans during the period 1992 to 2003 in England and Wales. J Clin Microbiol. 2005;43:2261–5.
- Navarro F, Perez-Trallero E, Marimon JM, Aliaga R, Gomariz M, Mirelis B. CMY-2-producing Salmonella enterica, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis and Escherichia coli strains isolated in Spain (October 1999–December 2000). J Antimicrob Chemother. 2001;48:383–9.
- Egorova S, Kaftyreva L, Grimont PAD, Weill FX. Prevalence and characterization of extended-spectrum cephalosporin-resistant non-typhoidal Salmonella isolates in adults in Saint Petersburg, Russia (2002–2005). Microb Drug Resist. 2007;13:102–7.
- Espié E, de Valk H, Vaillant V, Quelquejeu N, Le Querrec F, Weill FX. An outbreak of multidrug-resistant Salmonella enterica serotype Newport infections linked to the consumption of imported horse meat in France. Epidemiol Infect. 2005;133:373–6.
- Carattoli A, Miriagou V, Bertini A, Loli A, Colinon C, Villa L, Replicon typing of plasmids encoding resistance to newer beta-lactams. Emerg Infect Dis. 2006;12:1145–8.
- Carattoli A, Tosini F, Giles WP, Rupp ME, Hinrichs SH, Angulo FJ, Characterization of plasmids carrying CMY-2 from expanded-spectrum cephalosporin-resistant Salmonella strains isolated in the United States between 1996 and 1998. Antimicrob Agents Chemother. 2002;46:1269–72.
- Harbottle H, White DG, McDermott PF, Walker RD, Zhao S. Comparison of multilocus sequence typing, pulsed-field gel electrophoresis, and antimicrobial susceptibility typing for characterization of Salmonella enterica serotype Newport isolates. J Clin Microbiol. 2006;44:2449–57.
- Figure 1. Representative XbaI pulsed-field gel electrophoresis (PFGE) profiles of third-generation cephalosporin–resistant Salmonella Newport isolates studied. A dendrogram was generated with Bionumerics software (Applied Maths, Sint-Martens-Latem, Belgium). The PFGE profile (and...
- Figure 2. Representative PstI restriction profiles (A) and blaCMY-2 Southern hybridization (B) of plasmids from Escherichia coli DH10B transformants of CMY-2–producing Salmonella spp. clinical isolates. Lane M, Raoul molecular mass marker...
- Table. Resistance to specific antimicrobial drugs in Salmonella enterica serotype Newport from humans in France, 2000–2005
- Appendix Table. Characteristics of Samonella spp. isolates used in this study* 37 KB
1Current affiliation: Institut Pasteur, St. Petersburg, Russia.
2Current affiliation: Institut Pasteur, Casablanca, Morocco.
Please use the form below to submit correspondence to the authors or contact them at the following address:
François-Xavier Weill, Centre National de Référence des Salmonella, Laboratoire des Bactéries Pathogènes Entériques, Institut Pasteur, 28 Rue du Docteur Roux, 75724 Paris CEDEX 15, France;
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: July 09, 2010
- Page last updated: July 09, 2010
- Page last reviewed: July 09, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)